Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats

Pharmacology Research and Perspectives

Volumn 2, Issue 6, 2014, Pages

  Ding, Yuanyuan ^a   Qiu, Yanyan ^a   Jing, Li ^a,b   Thorn, David A ^a   Zhang, Yanan ^c   Li, Jun Xu ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c RTI INTERNATIONAL   (United States)

Author keywords

Allosteric modulator; cannabinoid CB1 receptor; food intake; hypothermia; ORG27569; rat

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; RIMONABANT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIORAL RESEARCH; BODY TEMPERATURE; CLONIDINE-INDUCED CATALEPSY; CONTROLLED STUDY; DATA ANALYSIS; ELEMENTAL ANALYSIS; EXPERIMENTAL CATALEPSY; FOOD INTAKE; GROOMING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHERMIA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SCRATCHING;

EID: 84939856351     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.69     Document Type: Article

References (47)

1. Adams IB, Compton DR, Martin BR (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284: 1209–1217.
2. Ahn KH, Mahmoud MM, Kendall DA (2012). Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem 287: 12070–12082.
3. Ahn KH, Mahmoud MM, Shim JY, Kendall DA (2013). Distinct roles of beta-arrestin 1 and beta-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem 288: 9790–9800.
4. Alexander SP, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164(Suppl. 1): S1–S324.
5. Cawston EE, Redmond WJ, Breen CM, Grimsey NL, Connor M, Glass M (2013). Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol 170: 893–907.
6. Christopoulos A, Kenakin T (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323–374.
7. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: PL113–PL117.
8. Darmani NA, Pandya DK (2000). Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 107: 931–945.
9. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004). Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15: 1–12.
10. Despres JP (2009). Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 15: 553–570.
11. Despres JP, Van Gaal L, Pi-Sunyer X, Scheen A (2008). Efficacy and safety of the weight-loss drug rimonabant. Lancet 371: 555, author reply 556–557.
12. Erdozain AM, Diez-Alarcia R, Meana JJ, Callado LF (2012). The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. Biochem Pharmacol 83: 260–268.
13. Fine PG, Rosenfeld MJ (2013). The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J 4: e0022.
14. Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, et al. (2014). In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol 25: 182–185.
15. Gessa GL, Orru A, Lai P, Maccioni P, Lecca R, Lobina C, et al. (2006). Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology 185: 248–254.
16. Giuffrida A, McMahon LR (2010). In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat 91: 90–103.
17. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932–1936.
18. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, et al. (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152: 805–814.
19. Jarbe TU, Andrzejewski ME, DiPatrizio NV (2002). Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73: 911–919.
20. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT (2013). An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46: 207–218.
21. Kirilly E, Gonda X, Bagdy G (2012). CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf) 205: 41–60.
22. Li JX, Koek W, France CP (2009). Food restriction and streptozotocin differentially modify sensitivity to the hypothermic effects of direct- and indirect-acting serotonin receptor agonists in rats. Eur J Pharmacol 613: 60–63.
23. Li JX, Zhang Y, Winter JC (2011). Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I(2) receptor ligands. Eur J Pharmacol 669: 59–65.
24. Li JX, Thorn DA, Qiu Y, Peng BW, Zhang Y (2014). Anti-hyperalgesic effects of imidazoline I receptor ligands in rat models of inflammatory and neuropathic pain. Br J Pharmacol 171: 1580–1590.
25. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (1988). Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247: 1046–1051.
26. Morena M, Campolongo P (2014). The endocannabinoid system: an emotional buffer in the modulation of memory function. Neurobiol Learn Mem 112: 30–43.
27. Navarro HA, Howard JL, Pollard GT, Carroll FI (2009). Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156: 1178–1184.
28. Pamplona FA, Ferreira J, Menezes de Lima O Jr, Duarte FS, Bento AF, Forner S, et al. (2012). Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci USA 109: 21134–21139.
29. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761–775.
30. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 1484–1495.
31. Rigamonti AE, Giordani C, Bonomo SM, Cella SG, Muller EE (2006). Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 542: 116–120.
32. Rowland NE, Mukherjee M, Robertson K (2001). Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159: 111–116.
33. Sampson C, Zhang Y, Del Bello F, Li JX (2012). Effects of imidazoline I2 receptor ligands on acute nociception in rats. NeuroReport 23: 73–77.
34. Serpell MG, Notcutt W, Collin C (2013). Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 260: 285–295.
35. Shore DM, Ballie GL, Hurst DP, Navas FJ III, Seltzman HH, Marcu JP, et al. (2014). Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem 289: 5828–5845.
36. Silvestri C, Di Marzo V (2013). The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 17: 475–490.
37. Singh H, Schulze DR, McMahon LR (2011). Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology 215: 665–675.
38. Thorn DA, Zhang Y, Peng BW, Winter JC, Li JX (2011). Effects of imidazoline I(2) receptor ligands on morphine- and tramadol-induced antinociception in rats. Eur J Pharmacol 670: 435–440.
39. Thorn DA, An XF, Zhang Y, Pigini M, Li JX (2012). Characterization of the hypothermic effects of imidazoline I(2) receptor agonists in rats. Br J Pharmacol 166: 1936–1945.
40. Traynor K (2007). Panel advises against rimonabant approval. Am J Health Syst Pharm 64: 1460–1461.
41. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A (2008). Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program. Diabetes Care 31(Suppl. 2): S229–S240.
42. Varga B, Kassai F, Gyertyan I (2012). Interactions of CB1 and mGlu5 receptor antagonists in food intake, anxiety and memory models in rats. Pharmacol Biochem Behav 103: 425–430.
43. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167: 103–111.
44. Vlachou S, Panagis G (2014). Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals. Curr Pharm Des 20: 2072–2088.
45. Ward SJ, Dykstra LA (2005). The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16: 381–388.
46. Ward SJ, Walker EA (2009). Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice. Behav Pharmacol 20: 605–613.
47. Witkamp R, Meijerink J (2014). The endocannabinoid system: an emerging key player in inflammation. Curr Opin Clin Nutr Metab Care 17: 130–138.